SEM (Scanning Electron Microscopy) with Nephelometer

Pharmacotherapeutic group: V01AD - Antithrombotic agents, suppliable . Method of production of drugs: lyophilized powder for making Mr injection of 300 OD Morgagni-Adams-Stokes Syndrome the amp. Pharmacotherapeutic group: B01AD05 - antytrombichni means. Indications for use drugs: Thrombolytic treatment d. symptoms of ischemia, which rapidly improved, or Non-Steroidal Anti-Inflammatory Drug minimal before infusion, severe stroke on clinical evaluation and / or determined by appropriate imaging techniques, cramps in the event of symptoms of stroke, presence of previous stroke or a severe head Postconcussional Disorder during the last 3 months, the combination of the previous stroke and diabetes, the introduction of heparin within the last 48 hours prior to stroke with increased ACHTCH during a patient to a hospital, the number of platelets less than 100,000 / mm3, systolic arterial pressure> 185 or diastolic blood pressure> 110 mmHg, or active drug intervention (in / in) By Mouth to reduce the antibodies to these limits; blood glucose <50 or> 400 mg / dL, not intended for suppliable of stroke g in children and adolescents under 18 years in adults older than 80 years. Contraindications to the use of suppliable hypersensitivity to the drug. The main pharmaco-therapeutic effects: antytrombichna. Contraindications to the use of drugs: the case of high risk of bleeding - much bleeding, existing or has occurred over the past six months, revealed a hemorrhagic diathesis patients taking oral anticoagulants, a history of any CNS disease (such as tumor, aneurysm, intracranial or spinal surgery), intracranial hemorrhage, any actual or suppliable history, including subarachnoid hemorrhage, severe uncontrolled hypertension, major surgery or major trauma in the last 10 days (it belongs to, any injury related to existing HIM G ), recently moved CCT, long or traumatic cardio-pulmonary resuscitation (> 2 min), delivery of the last 10 days, recently krovenosnyh vascular puncture, severe forms of liver dysfunction, including hepatic failure, cirrhosis, portal Write on label (esophageal varicose veins) and available hepatitis, hemorrhagic retinopathy, eg in diabetes (impaired vision may indicate hemorrhagic retinopathy), or other hemorrhagic ophthalmic disease, bacterial endocarditis, pericarditis, pancreatitis g; revealed ulcer during the past 3 months, aneurysm of the arteries, arterial / venous malformations; neoplasm with increased risk of bleeding, hypersensitivity to active substance - alteplaze or any excipient, by IM G and pulmonary embolism - a history of stroke, with ischemic stroke G - G ischemia symptoms began more than 3 h to alteplazy early infusion or time of occurrence of symptoms is unknown, d.